Cutaneous head and neck melanoma in OPTiM, a randomized phase 3 trial of talimogene laherparepvec versus granulocyte‐macrophage colony‐stimulating factor for the treatment of unresected stage IIIB/IIIC/IV melanoma

BACKGROUND: Cutaneous head and neck melanoma has poor outcomes and limited treatment options. In OPTiM, a phase 3 study in patients with unresectable stage IIIB/IIIC/IV melanoma, intralesional administration of the oncolytic virus talimogene laherparepvec improved durable response rate (DRR; continu...

Полное описание

Сохранить в:
Библиографические подробности
Опубликовано в: :Head Neck
Главные авторы: Andtbacka, Robert H. I., Agarwala, Sanjiv S., Ollila, David W., Hallmeyer, Sigrun, Milhem, Mohammed, Amatruda, Thomas, Nemunaitis, John J., Harrington, Kevin J., Chen, Lisa, Shilkrut, Mark, Ross, Merrick, Kaufman, Howard L.
Формат: Artigo
Язык:Inglês
Опубликовано: John Wiley and Sons Inc. 2016
Предметы:
Original Articles
Online-ссылка:https://ncbi.nlm.nih.gov/pmc/articles/PMC5129499/
https://ncbi.nlm.nih.gov/pubmed/27407058
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/hed.24522
Метки: Добавить метку
Нет меток, Требуется 1-ая метка записи!

Схожие документы